Effect of Dronedarone on Renal Function in Healthy Subjects

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2007 Jul 31

PMID 17662087

Citations 32

Authors

Yvonne Tschuppert

Thierry Buclin

Laura E Rothuizen

Laurent A Decosterd

Jacques Galleyrand

Christine Gaud

Jerome Biollaz

Affiliations

Soon will be listed here.

Abstract

Aims: To assess the effects of dronedarone on renal function and tubular cation handling.

Methods: Twelve healthy males were enrolled in a randomized, cross-over, placebo-controlled, double-blind study. They received 400 mg dronedarone or placebo twice daily for 7 days. Baseline and on-treatment renal function tests were performed under strict standardization of intakes, by assessing creatinine, sinistrin, para-amino-hippurate (PAH) and N-methylnicotinamide (NMN) CLs, and electrolyte excretion.

Results: Compared with placebo, dronedarone significantly decreased renal creatinine CL (mean 138-119 ml min(-1) after dronedarone vs. 142-149 ml min(-1) after placebo) and NMN CL (448-368 ml min(-1)vs. 435-430 ml min(-1)), but did not alter renal sinistrin CL, PAH CL and other renal parameters.

Conclusions: Dronedarone reduces renal creatinine and NMN clearance by about 18%, without evidence of an effect on GFR, renal plasma flow or electrolyte exchanges. This suggests a specific partial inhibition of tubular organic cation transporters (OCT). A limited increase in serum creatinine is therefore expected with dronedarone treatment, but does not mean there is a decline in renal function.

Citing Articles

Ventricular arrhythmias in the context of chronic kidney disease and electrolyte imbalance.

Masmoudi I, Dindane Z, Richter S, Ebert M Herzschrittmacherther Elektrophysiol. 2024; 35(3):211-218.

PMID: 39008102 DOI: 10.1007/s00399-024-01029-7.

Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug-Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective.

Choi H, Madari S, Huang F Clin Pharmacokinet. 2024; 63(6):735-749.

PMID: 38867094 PMC: 11222257. DOI: 10.1007/s40262-024-01385-0.

Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.

Thind M, Zareba W, Atar D, Crijns H, Zhu J, Pak H Clin Cardiol. 2022; 45(1):101-109.

PMID: 35019175 PMC: 8799050. DOI: 10.1002/clc.23765.

Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.

Vamos M, Oldgren J, Nam G, Lip G, Calkins H, Zhu J Eur Heart J Cardiovasc Pharmacother. 2021; 8(4):363-371.

PMID: 34958366 PMC: 9175188. DOI: 10.1093/ehjcvp/pvab090.

Renal Drug Transporters and Drug Interactions.

Ivanyuk A, Livio F, Biollaz J, Buclin T Clin Pharmacokinet. 2017; 56(8):825-892.

PMID: 28210973 DOI: 10.1007/s40262-017-0506-8.

References

Orlando R, Floreani M, Napoli E, Padrini R, Palatini P . Renal clearance of N(1)-methylnicotinamide: a sensitive marker of the severity of liver dysfunction in cirrhosis. Nephron. 2000; 84(1):32-9. DOI: 10.1159/000045536. View

Fujita T, Urban T, Leabman M, Fujita K, Giacomini K . Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci. 2005; 95(1):25-36. DOI: 10.1002/jps.20536. View

Musfeld C, Biollaz J, Belaz N, Kesselring U, Decosterd L . Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow. J Pharm Biomed Anal. 2001; 24(3):391-404. DOI: 10.1016/s0731-7085(00)00425-8. View

Dresser M, Leabman M, Giacomini K . Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci. 2001; 90(4):397-421. DOI: 10.1002/1520-6017(200104)90:4<397::aid-jps1000>3.0.co;2-d. View

Kusuhara H, Sugiyama Y . Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002; 78(1-3):43-54. DOI: 10.1016/s0168-3659(01)00480-1. View

Kemperman F, Surachno J, Krediet R, Arisz L . Cimetidine improves prediction of the glomerular filtration rate by the Cockcroft-Gault formula in renal transplant recipients. Transplantation. 2002; 73(5):770-4. DOI: 10.1097/00007890-200203150-00020. View

Sun W, Sarma J, Singh B . Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol. 2002; 39(5):677-84. DOI: 10.1097/00005344-200205000-00008. View

Brater D . Measurement of renal function during drug development. Br J Clin Pharmacol. 2002; 54(1):87-95. PMC: 1874392. DOI: 10.1046/j.1365-2125.2002.01625.x. View

You G . Structure, function, and regulation of renal organic anion transporters. Med Res Rev. 2002; 22(6):602-16. DOI: 10.1002/med.10019. View

10.

Gautier P, Guillemare E, Marion A, Bertrand J, Tourneur Y, Nisato D . Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol. 2003; 41(2):191-202. DOI: 10.1097/00005344-200302000-00007. View

11.

Touboul P, Brugada J, Capucci A, Crijns H, Edvardsson N, Hohnloser S . Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003; 24(16):1481-7. DOI: 10.1016/s0195-668x(03)00321-x. View

12.

Tett S, Kirkpatrick C, Gross A, McLachlan A . Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet. 2003; 42(14):1193-211. DOI: 10.2165/00003088-200342140-00002. View

13.

Dantzler W . Regulation of renal proximal and distal tubule transport: sodium, chloride and organic anions. Comp Biochem Physiol A Mol Integr Physiol. 2003; 136(3):453-78. DOI: 10.1016/s1095-6433(03)00135-1. View

14.

Lee W, Kim R . Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004; 44:137-66. DOI: 10.1146/annurev.pharmtox.44.101802.121856. View

15.

Damy T, Pousset F, Caplain H, Hulot J, Lechat P . Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004; 18(1):113-23. DOI: 10.1046/j.1472-8206.2003.00216.x. View

16.

Urakami Y, Kimura N, Okuda M, Inui K . Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res. 2004; 21(6):976-81. DOI: 10.1023/b:pham.0000029286.45788.ad. View

17.

Koepsell H . Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci. 2004; 25(7):375-81. DOI: 10.1016/j.tips.2004.05.005. View

18.

Burgess E, Blair A, Krichman K, Cutler R . Inhibition of renal creatinine secretion by cimetidine in humans. Ren Physiol. 1982; 5(1):27-30. DOI: 10.1159/000172836. View

19.

Somogyi A, Stockley C, Keal J, Rolan P, Bochner F . Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987; 23(5):545-51. PMC: 1386190. DOI: 10.1111/j.1365-2125.1987.tb03090.x. View

20.

Vlasses P, Kosoglou T, Chase S, Greenspon A, Lottes S, Andress E . Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. Arch Intern Med. 1989; 149(6):1350-3. View